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Report:  2 
We report the case of a 52-year old patient who presented with a 2-week history of localised 3 
erythema, swelling and discomfort of the left palm during her 3rd cycle of palliative 4 
carboplatin and doxorubicin (Caelyx) for metastatic ovarian cancer. On clinical examination 5 
there was marked unilateral left hand oedema with extensive erythema and early bullae 6 
formation of the palmar aspect consistent with grade 3 erythrodysesthaesia (Fig 1). Very mild 7 
erythema was noted on the right palm. The soles and rest of her skin examination, including 8 
mucosa, were unremarkable.  She had had no reaction with her previous two cycles. However 9 
seven days prior to this third cycle she had developed sudden onset of left neck swelling 10 
which was diagnosed on Doppler ultrasound scanning as a deep vein thrombosis (DVT) 11 
affecting the left internal jugular and subclavian veins (Fig. 1b,c).  She was treated with very 12 
potent topical steroids, emollients and a soap substitute for the palmoplantar 13 
erythrodysesthaesia and therapeutic enoxaparin injections for the DVT.  After a short 14 
treatment break her neck swelling improved and she received a 4th cycle which resulted in a 15 
similar but less severe reaction  16 
Conventional chemotherapy plays a significant role in cancer management but is often 17 
associated with adverse cutaneous reactions. Pegylated liposomal doxorubicin (PLD) is 18 
widely used in the treatment of solid tumours such as ovarian, breast and AIDS-related 19 
Kaposi’s sarcoma. It is characteristically known to cause hand-foot syndrome1, also known as 20 
palmar-plantar erythrodysesthaesia (PPE). A similar reaction has been observed with 21 
capecitabine, daunorubicin, sorafenib, 5-fluorouracil and tyrosine-kinase inhibitors.  22 
The typical clinical presentation includes symmetrical palmoplantar erythema, swelling and 23 
desquamation. The exact mechanism of the syndrome remains unknown. Drug extravasation 24 
due to long-term circulation of metabolically stable pegylated doxorubicin and creation of 1 
reactive oxygen species (pro-inflammatory and directly toxic to the keratinocytes) in the 2 
presence of metal ions in the skin, is thought to be implicated. The drug penetrates capillary 3 
walls very easily and these are concentrated at the fingertips and soles of the feet where the 4 
blood flow is high.  5 
Rash development seems to be independent of the number of PLD cycles preceding 6 
chemotherapy regimes. It has been estimated that 77.5% of PPE cases occur within the first 3 7 
infusion cycles. The development of the syndrome has been related to a lower risk of disease 8 
progression and progression-free survival2. Tumour cell exposure to PLD was found to be 9 
higher in patients who experienced the rash compared to those without. Therefore rash 10 
development may potentially serve as a surrogate marker for treatment success. This may 11 
have important clinical implications as dose reduction or treatment interruption, because of 12 
rash development, may actually negatively affect treatment outcome in patients that are 13 
actually most likely to benefit.  14 
There are no known preventative or treatment strategies; the condition is best treated 15 
symptomatically with potent topical steroids. Some evidence supports the use of 200-400mg 16 
twice daily of celecoxib, a COX-2 non-steroidal anti-inflammatory inhibitor, in the 17 
prevention of PPE development. A zebra-fish model of pegylated liposomal doxorubicin-18 
induced hand-foot syndrome was recently described in the literature by Chen YH et al; the 19 
group showed reversible skin toxicity upon discontinuation of the drug which may serve as a 20 
screening model for agents managing PPE3.  21 
Unilateral hand-foot syndrome has only been reported thrice in the literature, following 22 
capecitabine. No imaging to look for associated DVT was documented in the reported cases4-23 
6.  24 
To the best of our knowledge, this is the first reported case of caelyx-induced unilateral PPE. 1 
Caelyx is much more frequently associated with PPE and therefore the most likely culprit7. 2 
We propose this has occurred because of impaired venous return at the clot level and 3 
therefore higher concentration of a toxic drug in the affected limb with increased the drug 4 
bioavailability and increase toxicity.  5 
By reporting DVT as a potential explanation for the rare phenomenon of unilateral PPE we 6 
recommend that clinicians should have a high index of suspicion of thrombo-occlusive events 7 
in patients with malignancy presenting with atypical or unilateral skin reactions. 8 
 9 
 10 
Figure 1:  11 
 12 
Legend: (a). Grade 3 reaction of the left hand with dysesthaesia, pain, erythema and oedema 13 
(b). Thrombus in the left internal jugular vein. (c) Thrombus in the left subclavian vein 14 
 15 
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